Rejuvenation Technologies Inc.
Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Extends mouse lifespan by equivalent of 10 years in humans. Reverses 5-10 years of telomere shortening with one dose in one day. Preclinical efficacy in 4 organ systems including immune system. Entering clinical stage. CEO is Subject #1 in longevity trial. 50+ granted patents, 7 patent families. FDA INTERACT cleared. Raising $10M seed extension ($2M+ wired) to fund 3 investigator-initiated tria
Y Combinator
yc-company-directory #1320Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Extends mouse lifespan by equivalent of 10 years in humans. Reverses 5-10 years of telomere shortening with one dose in one day. Preclinical efficacy in 4 organ systems including immune system. Entering clinical stage. CEO is Subject #1 in longevity trial. 50+ granted patents, 7 patent families. FDA INTERACT cleared. Raising $10M seed extension ($2M+ wired) to fund 3 investigator-initiated tria
sourceRejuvenation Technologies Inc. is classified as Healthcare from source descriptions and fund-directory context. Similar companies below are ranked from offline product facets and meaningful description overlap; category and source affiliation can only strengthen an existing product match. For lookup-created rows, the profile starts as pending enrichment until deeper source collection runs.
Local clusters rerank extracted product concepts and description terms. The generated graph remains the fallback for sparse descriptions: offline reciprocal product-similarity graph: extracted concepts + description terms + bounded category/affiliation boosts. Minimum fallback score: 0; max competitors: 6.
Companies similar to Rejuvenation Technologies Inc.
A deterministic local cluster built from offline product facets and meaningful description terms. Category and selected-institution affiliation provide bounded tie-breaks. Open any peer to continue exploring its cluster.
SFA Therapeutics
match 57SFA Therapeutics is creating therapeutically-tailored oral drugs that regulate the immune system; with a focus on autoimmune diseases and cancers that originate from chronic inflammation. There are over 300 million patients who suffer from autoimmune diseases. Our treatment is designed to block the root cause of many of these chronic inflammatory diseases, with safe oral drugs. We have strong clinical data from a phase 1b clinical trial in psoriasis, and human data in pancreatic cancer, uveitis
shared product terms: drug, human, system, immune; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator
Convexia
match 54An AI-maximalist pharma platform. We use agents to buy drugs, run clinical trials, and sell for a profit. 10x faster and 20x leaner than incumbents. Sourcing Agent: Mines public/private databases and unstructured global data to surface overlooked preclinical candidates. Scientific Agent: Runs comp bio models (ESM-3, RFdiffusion, Boltz-2, AlphaFold) to assess safety and efficacy in silico. Commercial Agent: Analyzes FDA incentives, pricing dynamics, TAM, competitive landscape, and payer alignment
shared product terms: drug, clinical, trial, preclinical; shared product theme: health and clinical care; shared affiliation: Y Combinator
Vena Medical
match 49Pre-clinical results published in the Journal of Neuro-Interventional Surgery. Technology presented at the World Live Neurovascular Conference. Technology selected as a top 3 finalist for Innovator of the Year by the Congress of Neurological Surgeons. Raised a Series A to fund commercialization (FDA Clearance, Health Canada, ISO 13485, First-in-man and early revenue).
shared product terms: year, clinical, fda, rais; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator
zPREDICTA
match 46zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response
shared product terms: drug, human, efficacy, organ; shared product theme: health and clinical care; shared affiliation: Y Combinator
Trestle Biotherapeutics
match 41We are developing an implantable therapeutic tissue that will be surgically delivered to patients suffering from end stage renal disease. Upon implantation, this tissue will supplement the patient's renal function, eliminating their dependency on dialysis and improving their disease status. This has the potential to not only get these patients off dialysis - a significant impact for them and their families - but to greatly extend the time required before kidney transplantation is essential.
shared product terms: essential, extend, stage, familie; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator
Kura AI
match 33Kura breaks 87% on the WebVoyager Benchmark. That is 31% better than Claude's Computer Use demo and 14% better than the previous State of the Art. In 10 years there will be more AI agents on the internet than humans. Kura is SOTA for giving AI agents the tools for interacting with websites.
shared product terms: 10, year, human, interact; shared affiliation: Y Combinator